← SynDRA
setmelanotide
SynDRA canonical compound SYN0042180 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | MC1R | MC3R | MC4R |
|---|
| Mechanism of action | melanocortin receptor agonist |
|---|
All known targets
Mechanisms of action (all sources)
- MC4R AGONIST
- Melanocortin receptor 4 agonist
- melanocortin receptor agonist
Drug classes
- Melanocortin 4 Receptor Agonist
- Melanocortin 4 Receptor Agonists
ATC classes
- A08A · ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Cross-references
Synonyms
- setmelanotide hydrochloride
- setmelanotide acetate
- imcivree
- RM-493
- Setmelanotida
- BIM-22493
- Imcivree
- UNII-N7T15V1FUY
- N7T15V1FUY
- Setmelanotide [USAN:INN]
- GTPL9272
- CHEMBL3301624
- CS-6399
- DB11700
- HY-19870
- L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2->
- 8)-disulfide
- (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-d
- Setmelanotidum
- RefChem:58308
- DTXCID101517326
- Setmelanotide (RM-493)
- Setmelanotide [USAN]
- SETMELANOTIDE [INN]
- SETMELANOTIDE [WHO-DD]
- orb1708548
- SCHEMBL21840385
- SCHEMBL29359327
- SCHEMBL29361699
- SCHEMBL30014071
- GLXC-21144
- GLXC-23661
- C49H68N18O9S2
- EX-A5542
- BDBM50581319
- AT23144
- IRC-022493
- BP-50424
Reported adverse events
- Arthralgia
- Back pain
- Depression
- Dizziness
- Fatigue
- Headache
- Injection site reaction
- Nausea
- Skin hyperpigmentation
- Vertigo
- Spontaneous penile erection
- Injection
Look up setmelanotide in the interactive SynDRA portal →